A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
Status:
Recruiting
Trial end date:
2022-12-12
Target enrollment:
Participant gender:
Summary
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and
pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple
ascending doses in participants with Non-alcoholic Steatohepatitis (NASH) with fibrosis Stage
0 to 3 and homozygous for the patatin-like phospholipase domain-containing 3 (PNPLA3) 148M
risk allele.